Literature DB >> 11683787

Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual and fatal triad in a patient 13 months post Rituximab and autologous stem cell transplantation.

L M McIlwaine1, E J Fitzsimons, R L Soutar.   

Abstract

We report a case of varicella-zoster virus (VZV) infection associated with severe abdominal pain, inappropriate antidiuretic hormone (ADH) secretion (SIADH) and death, 13 months post-autologous peripheral blood stem cell transplantation (PBSCT). This unusual clinical triad has been reported twice in the setting of allogeneic bone marrow transplantation, however it has not been reported after autologous transplantation and never so long after transplantation. We speculate as to why this occurred, as early recognition might have altered the clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683787     DOI: 10.1046/j.1365-2257.2001.00397.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  4 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

Review 2.  Syndrome of inappropriate secretion of antidiuretic hormone associated with localized herpes zoster ophthalmicus.

Authors:  Chih-Chiang Wang; Jeng-Chuan Shiang; Jiann-Tomg Chen; Shih-Hua Lin
Journal:  J Gen Intern Med       Date:  2010-09-29       Impact factor: 5.128

Review 3.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 4.  Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients.

Authors:  Sabine Breuer; Margit Rauch; Susanne Matthes-Martin; Thomas Lion
Journal:  Mol Diagn Ther       Date:  2012-04-01       Impact factor: 4.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.